Abivax (ABVX) Competitors

$121.99 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$123.25 +1.26 (+1.04%)

As of 05/22/2026 07:59 PM Eastern

ABVX vs. ONC, RVMD, INSM, BNTX, and ROIV

Should you buy Abivax stock or one of its competitors? MarketBeat compares Abivax with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abivax include BeOne Medicines (ONC), Revolution Medicines (RVMD), Insmed (INSM), BioNTech (BNTX), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Abivax compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

BeOne Medicines has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.37	$286.93M	$4.47	69.41
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

BeOne Medicines has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Abivax has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

BeOne Medicines has a net margin of 8.94% compared to Abivax's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Abivax	N/A	-146.43%	-88.69%

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Abivax had 3 more articles in the media than BeOne Medicines. MarketBeat recorded 7 mentions for Abivax and 4 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.48 beat Abivax's score of 0.38 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines currently has a consensus price target of $389.15, indicating a potential upside of 25.43%. Abivax has a consensus price target of $137.15, indicating a potential upside of 12.43%. Given BeOne Medicines' higher possible upside, equities research analysts plainly believe BeOne Medicines is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

BeOne Medicines beats Abivax on 11 of the 15 factors compared between the two stocks.

How does Abivax compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Abivax has lower revenue, but higher earnings than Revolution Medicines. Abivax is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,782.53	-$1.13B	-$7.07	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Revolution Medicines' return on equity of -83.22% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Abivax	N/A	-146.43%	-88.69%

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Revolution Medicines had 2 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Revolution Medicines and 7 mentions for Abivax. Revolution Medicines' average media sentiment score of 1.16 beat Abivax's score of 0.38 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revolution Medicines has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Abivax has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Revolution Medicines presently has a consensus price target of $111.35, indicating a potential downside of 26.53%. Abivax has a consensus price target of $137.15, indicating a potential upside of 12.43%. Given Abivax's higher possible upside, analysts clearly believe Abivax is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.00
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Revolution Medicines beats Abivax on 12 of the 15 factors compared between the two stocks.

How does Abivax compare to Insmed?

Abivax (NASDAQ:ABVX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Abivax has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-146.43%	-88.69%
Insmed	-144.44%	-130.11%	-51.57%

Abivax has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Insmed has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

47.9% of Abivax shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abivax has higher earnings, but lower revenue than Insmed. Abivax is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Insmed	$606.42M	37.97	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 12 more articles in the media than Abivax. MarketBeat recorded 19 mentions for Insmed and 7 mentions for Abivax. Insmed's average media sentiment score of 1.08 beat Abivax's score of 0.38 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	15 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Abivax currently has a consensus price target of $137.15, indicating a potential upside of 12.43%. Insmed has a consensus price target of $210.95, indicating a potential upside of 98.56%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Insmed beats Abivax on 11 of the 15 factors compared between the two stocks.

How does Abivax compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, BioNTech and BioNTech both had 7 articles in the media. BioNTech's average media sentiment score of 0.79 beat Abivax's score of 0.38 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioNTech has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Abivax has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

BioNTech presently has a consensus target price of $128.44, suggesting a potential upside of 39.39%. Abivax has a consensus target price of $137.15, suggesting a potential upside of 12.43%. Given BioNTech's higher possible upside, equities research analysts plainly believe BioNTech is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Abivax has lower revenue, but higher earnings than BioNTech. Abivax is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.18	-$1.29B	-$5.88	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Abivax has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Abivax	N/A	-146.43%	-88.69%

15.5% of BioNTech shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

BioNTech beats Abivax on 8 of the 14 factors compared between the two stocks.

How does Abivax compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Abivax	N/A	-146.43%	-88.69%

In the previous week, Roivant Sciences had 19 more articles in the media than Abivax. MarketBeat recorded 26 mentions for Roivant Sciences and 7 mentions for Abivax. Roivant Sciences' average media sentiment score of 0.43 beat Abivax's score of 0.38 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	6 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences presently has a consensus price target of $33.05, indicating a potential upside of 10.30%. Abivax has a consensus price target of $137.15, indicating a potential upside of 12.43%. Given Abivax's stronger consensus rating and higher possible upside, analysts clearly believe Abivax is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Roivant Sciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Abivax has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,595.93	-$171.98M	-$0.60	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Roivant Sciences beats Abivax on 10 of the 16 factors compared between the two stocks.

Get Abivax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVX vs. The Competition

Export

Metric	Abivax	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.72B	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-23.41	18.74	21.22	25.65
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	18.57	7.09	10.37	7.14
Net Income	-$380.27M	$24.45M	$3.57B	$335.98M
7 Day Performance	7.43%	5.45%	6.01%	3.56%
1 Month Performance	6.49%	2.43%	3.52%	2.54%
1 Year Performance	2,051.50%	62.98%	34.13%	35.05%

Abivax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVX Abivax	2.9521 of 5 stars	$121.99 flat	$137.15 +12.4%	+2,051.5%	$9.72B	N/A	N/A	61	Earnings Report Analyst Upgrade Gap Up
ONC BeOne Medicines	4.1624 of 5 stars	$293.09 -0.1%	$389.15 +32.8%	+28.5%	$32.18B	$5.34B	65.57	12,000
RVMD Revolution Medicines	2.6504 of 5 stars	$144.37 -0.9%	$108.88 -24.6%	+281.1%	$30.97B	$11.58M	N/A	250	Positive News
INSM Insmed	3.503 of 5 stars	$107.15 -1.8%	$210.95 +96.9%	+57.3%	$23.66B	$819.56M	N/A	1,664	Positive News Insider Trade Gap Up
BNTX BioNTech	3.7778 of 5 stars	$88.85 -0.8%	$130.60 +47.0%	-6.6%	$22.65B	$3.25B	N/A	7,807	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVX) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abivax (ABVX) Competitors

ABVX vs. ONC, RVMD, INSM, BNTX, and ROIV

How does Abivax compare to BeOne Medicines?

Summary

How does Abivax compare to Revolution Medicines?

Summary

How does Abivax compare to Insmed?

Summary

How does Abivax compare to BioNTech?

Summary

How does Abivax compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX vs. The Competition

Abivax Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abivax (ABVX) Competitors

ABVX vs. ONC, RVMD, INSM, BNTX, and ROIV

How does Abivax compare to BeOne Medicines?

Which has higher earnings & valuation, ONC or ABVX?

Which has more risk & volatility, ONC or ABVX?

Is ONC or ABVX more profitable?

Do institutionals and insiders believe in ONC or ABVX?

Does the media refer more to ONC or ABVX?

Do analysts prefer ONC or ABVX?

Summary

How does Abivax compare to Revolution Medicines?

Which has preferable earnings & valuation, RVMD or ABVX?

Is RVMD or ABVX more profitable?

Do institutionals and insiders believe in RVMD or ABVX?

Does the media refer more to RVMD or ABVX?

Which has more volatility & risk, RVMD or ABVX?

Do analysts recommend RVMD or ABVX?

Summary

How does Abivax compare to Insmed?

Is ABVX or INSM more profitable?

Which has more risk & volatility, ABVX or INSM?

Do insiders & institutionals hold more shares of ABVX or INSM?

Which has stronger earnings and valuation, ABVX or INSM?

Does the media favor ABVX or INSM?

Do analysts prefer ABVX or INSM?

Summary

How does Abivax compare to BioNTech?

Does the media favor BNTX or ABVX?

Which has more risk and volatility, BNTX or ABVX?

Do analysts rate BNTX or ABVX?

Which has preferable valuation and earnings, BNTX or ABVX?

Is BNTX or ABVX more profitable?

Do insiders & institutionals believe in BNTX or ABVX?

Summary

How does Abivax compare to Roivant Sciences?

Is ROIV or ABVX more profitable?

Does the media favor ROIV or ABVX?

Do analysts prefer ROIV or ABVX?

Which has more volatility and risk, ROIV or ABVX?

Which has stronger earnings & valuation, ROIV or ABVX?

Do institutionals & insiders have more ownership in ROIV or ABVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX vs. The Competition

Abivax Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools